ABOUT SCITECH
Company Overview
SciTech Development Inc., headquartered in Michigan, is an oncology-focused, clinical-stage pharmaceutical company led by a world-class team. SciTech is committed to developing innovative, effective, and affordable cancer therapeutics that address unmet medical needs to bring hope to patients around the globe.
SciTech has developed ST-001 nanoFenretinide (ST-001), a patented new drug with clinical trials in progress for T-cell lymphoma (a form of non-Hodgkin lymphoma). The FDA has granted ST-001 Orphan Drug Designation that allows for 7 years of market exclusivity once approved.
ST-001 combines the active drug fenretinide with biocompatible phospholipids in a unique delivery system, enabling the rapid IV infusion of high-dose fenretinide.
Preliminary Phase 1a clinical trial data indicates successful drug delivery to targeted tissue, enhanced bioavailability, a positive safety profile, as well as partial and stable disease responses in patients. This signals the potential for a new approach to cancer treatment.
The FDA has also approved a second IND that allows clinical trials to proceed in small cell lung cancer, targeted for Q/2/Q3, 2025.
Leadership Team
Earle T. Holsapple III,
President & Co-Founder
Successfully served as CEO/COO of six profitable companies. Raised significant capital for four companies ranging in focus from international trade to complex life science startups. Led the Center for Cancer Economic, Technology Assessment, Innovation & Development (CETAID) for the Karmanos Cancer Institute (KCI).
Ralph E. Parchment, PhD,
Chief Scientific Advisor & Co-Founder
Principal inventor of the SciTech drug delivery technology and ST-001 at Wayne State University/Karmanos Cancer Institute (KCI). Accomplished pharmacologist and director of the multi-laboratory program at the Frederick National Laboratory for Cancer Research, managing efforts to create, evaluate and develop new drug compounds.
Andrew J. Stumpf
Chief Financial Officer
20+ years of experience as a finance professional in private equity, investment banking, corporate finance, and public accounting. Partner with Storm Lake Capital, a private equity firm. Managed portfolio companies to include financial planning, reporting, budgeting, and audit/tax filings.
Ali Moiin
Medical Director
Board Certified and practicing dermatologist with extensive experience in treating Cutaneous T-cell Lymphoma patients. Clinical Professor at Wayne State University, School of Medicine. Doctorate of Medicine from UC, Davis, BS in pharmacology and Master’s in biology from the UC, Santa Barbara.
Louis M. Scarmoutzos, PhD
Vice President of Operations
30+ years of business and academic experience in the biotech, chemistry, and pharmaceutical industries; Advisory positions include National Institute of Health (NIH), National Science Foundation (NSF) and Larta Institute; Post-Doctoral Fellow in Chemistry/Chemical Biology at Harvard University.
John Chapman
Senior Financial Advisor
Senior Partner and member of the Board of Directors for KPMG LLP and KPMG Americas, serving as Global Chair of the firm's Pharmaceuticals Practice with multinational corporations. Recognized SEC financial expert and provides advisory on complex financial matters including IPO’s, M&A, and valuations.
David Schaffer
Director, Investor Relations and Business Development
Executive with 30 years of experience in global equity capital markets, investment banking, equity market research, investor relations and strategic advisory to public/private funds. Executive positions at Raymond James Global Equity Markets, Kaufman, Advest with P&L accountability, product development and business planning.
Ken Massey
Strategic Operations Advisor
Senior Director of Venture Development and Adjunct Professor of Pharmacology at Wayne State University. Key positions at Pfizer overseeing scientific and operations for multiple drug development programs culminating in FDA approval. Assistant professor at the U. of Michigan Medical School, and as Managing Director of LifeLine Ventures.
Michael Burns
Director, Corporate and
Strategic Development
40+ years of extensive pharmaceutical industry experience that includes R&D, product development, sales & marketing, licensing, and M&A; Past President and COO of Ferndale Pharma, specialize in the development, manufacture and distribution of prescription, over-the-counter drug products. Former CEO of Repromedix Corporation.
Strategic and Medical Advisors
-
Larisa Geskin, M.D.; Director, Comprehensive Cutaneous Oncology Center at Columbia University
-
Ajay Gopal, M.D.; Medical Director of Clinical Research and Hematology at Fred Hutch Cancer Center
-
Tony Polverino, Ph.D.; Former Executive Director of Amgen, Former CSO of Kite Pharmaceuticals
-
Bill Werkmeister, MBA; Partner, HRN Family Office, Board of National Foundation for Cancer Research